Mark Cunningham is the UK Managing Director at PriceHubble, Europe’s leader in property data solutions for finance and real estate. He brings deep expertise in property data, analytics, and digital transformation, with a strong track record of helping financial institutions and real estate players unlock value through data-driven insights.
Prior to joining PriceHubble, Mark co-founded WhenFresh, a leading provider of UK property data and analytics for banks, insurers, and utilities that was acquired by PriceHubble at the end of 2023, becoming a key part of its UK operations. With a background in venture start-ups, commercial development, and data architecture, Mark has founded and led several businesses at the intersection of data and innovation
Mark is Head of Behaviour Change at reChanneld, a Nordics company that blends the learnings from behavioural economics and cutting edge technology to help motivate consumers into taking action. Tech on its own, without a profound understanding of human preferences and behaviours, has a habit of missing the mark. By putting consumer behaviour front and centre of any tech solution, we have managed to deliver behaviour change at scale for our clients. Together, our team has nudged millions of customers towards faster, more efficient digital self-serve with intuitive signposting tools and simple user chosen pathways.
Kapil Ahuja is Partner Director and CTO at Nagarro Ventures & Studios, where he leads the practice designing and building AI-native digital experience platforms for global enterprises.
His view: most CX transformation fails not at the vision layer but at the execution gap. Real progress requires AI working on both sides: in the experience the customer encounters, and in the build process that creates it. He writes and speaks on intent-driven AI development, the principle that AI should work from human intent across the full build cycle, not just as a feature in the finished product. He works directly with CMOs and CXOs on platform strategy, experience architecture, and end-to-end delivery.
Dr. Mohamed Fawzy Ibrahim Hassan, Professor of Paediatric Oncology, Cairo University | Director, Clinical Research Centre, CCHE-57357
Dr. Fawzy is a Paediatric Oncologist with more than three decades of clinical, research and academic experience. As a graduate of Cairo University’s Kasr El-Aini School of Medicine in 1992, earned his doctoral degree (MD) in Paediatric Oncology in 2003 and an MBA in Healthcare Management in 2018.
Dr. Fawzy serves as a Professor of Pediatric Oncology at Cairo University since 2014 and holds the position of Director of the Clinical Research Centre at the Children’s Cancer Hospital Egypt (CCHE-57357). Leading the strategic direction of clinical research at CCHE/57357, with a strong emphasis on regulatory compliance, ethical oversight, and quality conduction of clinical research where translational research comes in the heart of his role.
Dr. Fawzy is also the team leader of the Neuroblastoma Study Group, with a main focus on improving the management and outcomes of neuroblastoma in the low- and middle-income countries (LMICs).
On the administrative front, Dr. Fawzy played a pivotal role in establishing and operating the CCHE branch in Tanta as a 60-bed tertiary care pediatric oncology center serving Egypt’s Delta region. Served as Hospital Director from 2015 to 2023, overseeing clinical operations, talent development as well as best allocation of resources.
Academic contribution includes serving as Associate Editor for the Journal of the Egyptian National Cancer Institute (JENCI) and as a reviewer for the Faculty Promotion Committee of Egypt’s Supreme Council of Universities. He is a co-founder of the Egyptian Pediatric Hematology Oncology Society (EPHOS), member of the Board of Directors for the Paediatric Oncology East and Mediterranean (POEM). He is also an active member of several international scientific organizations including SIOP, ANRA, and GNN.
Dina Mohamed Elgalaly serves as Clinical Operation Manager at the Clinical Research Center of 57357 / Children’s Cancer Hospital, where she leads the planning, execution, and management of clinical trials. Holding a bachelor degree in Pharmacy, she brings over 10 years of experience in managing clinical trials in compliance with international regulatory standards, including FDA, ICH‑GCP, and Egyptian authorities such as SCCRE and EDA.
Her responsibilities include feasibility assessment, protocol development, site coordination, and oversight of multidisciplinary teams comprising research coordinators, pharmacists, and nursing staff. She ensures that all clinical activities are conducted with precision, integrity, and adherence to ethical, regulatory standards and institutional goals, while maintaining high performance across operational metrics.
She leads training initiatives, manages risk mitigation strategies, and maintains quality control throughout all phases of clinical research. She works closely with Principal Investigators, sponsors, and institutional leadership to ensure seamless trial conduct, timely patient recruitment, and robust data quality. Additionally, she manages budgets, oversees vendor relationships, and handles regulatory submissions, serving as the primary liaison for external audits and sponsor communications.
She is certified in Good Clinical Practice and has completed training in the Principles of Clinical and Translational Research from Harvard. She completed a Master’s degree in Pharmacology and an MBA, further strengthening her expertise in clinical operations and leadership. With a deep commitment to excellence and innovation in clinical research, she strives to build collaborative partnerships that advance therapeutic development and improve patient outcomes.
Kay Faulkner is Divisional Director of Operations for Research and Innovation at The Christie NHS Foundation Trust, where she leads delivery of the organisation’s research and innovation strategy across one of Europe’s largest cancer centres.
Kay joined The Christie in December 2023, bringing extensive experience in NHS research leadership, system collaboration and academic partnerships. Prior to this, she was Associate Director for Research, Innovation and Education at University Hospitals Northamptonshire NHS Group, where she played a key role in achieving University Hospital status, doubling research participation, and strengthening strategic partnerships with the University of Leicester and University Hospitals of Leicester. This work contributed to Northamptonshire’s alignment with the NIHR Leicester Biomedical Research Centre and Clinical Research Facility. Kay also held a system leadership role for Research and Innovation within the Northamptonshire Integrated Care Board.
Kay began her NHS career at Manchester University NHS Foundation Trust, working in Research and Innovation in partnership with the Manchester Life Sciences campus at Citylabs. Earlier in her career, she worked across the public and academic sectors, including roles within the Greater Manchester Criminal Justice Board and at Manchester Metropolitan University and the University of Plymouth, focusing on building impactful collaborations with the NHS, public sector and charities.
